ARIAD Names Sarah J. Schlesinger, M.D. of Rockefeller University to Its Board of Directors

  ARIAD Names Sarah J. Schlesinger, M.D. of Rockefeller University to Its
  Board of Directors

Business Wire

CAMBRIDGE, Mass. -- July 17, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of
Sarah J. Schlesinger, M.D., senior attending physician and associate professor
of clinical investigation in the Laboratory of Cellular Physiology and
Immunology at The Rockefeller University, to its Board of Directors. Dr.
Schlesinger, 53, is a prominent clinical investigator and immunologist who has
spent more than 20 years working in the field of cellular immunity, including
as clinical director of the laboratory led by the late Ralph M. Steinman,
M.D., 2011 Nobel Laureate in Physiology or Medicine.

ARIAD Names Sarah J. Schlesinger, M.D. of Rockefeller University to Its Board
of Directors (Photo: B ...

ARIAD Names Sarah J. Schlesinger, M.D. of Rockefeller University to Its Board
of Directors (Photo: Business Wire)

“Dr. Schlesinger brings a deep understanding of translational medicine,
clinical research, and immunology to our Board of Directors,” stated Harvey J.
Berger, M.D., chairman and chief executive officer of ARIAD. “Sarah embodies
one of our most important corporate values – clinical scholarship – and
further enhances our commitment to cancer patients in need of new therapies.
We anticipate that she will contribute greatly to our Board and to the
evolution of our long-term strategy, especially as the fields of molecularly
targeted therapy and immunotherapy converge.”

Dr. Schlesinger’s research has focused on the clinical manipulation of the
immune system’s dendritic cells to elicit immunity to cancer and HIV. Working
closely with Dr. Steinman, she used dendritic cells to study and design novel
treatments that may be able to harness the immune system in a disease-specific
approach. She has designed and conducted clinical trials employing the
techniques of immunology and dendritic-cell biology, which have led to a
better understanding of human diseases and their potential treatments.

In addition to leading clinical trials at the Rockefeller University Hospital,
she is co-director of the University’s Clinical Scholars program and the
Certificate in Clinical and Translational Sciences program. She chairs the
research education and training committee of the Center for Clinical and
Translational Science at Rockefeller. Widely published in her field, Dr.
Schlesinger has been recognized with numerous awards for her research and
teaching.

“ARIAD’s vision is to improve the lives of cancer patients through the
development of innovative medicines. That vision and the Company’s emphasis on
discovering and developing new treatments based on its internal research
differentiate ARIAD from other companies, large or small,” noted Dr.
Schlesinger. “I am honored to serve on the ARIAD Board and to bring my
experience in clinical development to the outstanding team at ARIAD.”

Dr. Schlesinger trained in surgery at the Albert Einstein College of Medicine
(1985-1987) and in pathology at the New York Hospital (1987-1990), where she
served as chief resident. She held faculty positions at Cornell University
Medical College (1990-1991), State University of New York at Buffalo
(1991-1994) and Georgetown University School of Medicine (1995-2002). In 1996,
she became a research physician in the Division of Retrovirology at the Walter
Reed Army Institute of Research and then worked as a scientist in vaccine
research at the International AIDS Vaccine Initiative.

In 2002, she came to Rockefeller University as a member of the adjunct faculty
in the Laboratory of Cellular Physiology and Immunology, and then in 2003, she
was appointed as a research associate professor with a joint appointment at
the Aaron Diamond AIDS Research Center. In 2007, she became associate
professor of clinical investigation at Rockefeller University and clinical
director of the Steinman laboratory.

Dr. Schlesinger received her bachelor’s degree from Wellesley College and her
M.D. degree from Rush Medical College.

References:

Harmon K., “How Ralph Steinman Raced to Develop a Cancer Vaccine – And Save
His Life.” Scientific American, December 20, 2011.
http://www.scientificamerican.com/article.cfm?id=the-patient-scientist.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and
Lausanne, Switzerland, is an integrated global oncology company focused on
transforming the lives of cancer patients with breakthrough medicines. ARIAD
is working on new medicines to advance the treatment of various forms of
chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer medicines.
For additional information, visit http://www.ariad.com or follow ARIAD on
Twitter (@ARIADPharm).

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130717005283/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50671570&lang=en

Contact:

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
 
Press spacebar to pause and continue. Press esc to stop.